Clinical trial NCT06292156: tACS Treatment for Cognitive Impairments in Methamphetamine Addicts
Official title: tACS Treatment for Cognitive Impairments in Methamphetamine Addicts
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Methamphetamine Abuse
Keywords: Methamphetamine patients
Cognitive impairments
tACS
Lead sponsor: Beijing HuiLongGuan Hospital
Sponsor class: OTHER
First posted: 2024-03-04
Enrollment: 300
Sex: ALL
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: 1. To evaluate the cognitive function of methamphetamine Patients.
2. Investigate the pathological mechanism of methamphetamine patients from the aspects of EEG and biology;
3. The investigators investigated the effects of transcranial alternating current stimulation (tACS) on cognitive impairments in methamphetamine patients


Eligibility criteria: Inclusion Criteria:

* Clinical diagnosis diagnosis of methamphetamine use disorder according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5)
* None of participants had mixed use of other drugs
* None of participants had physical disability
* None of participants had acute physical or mental illness, hallucinations, acute withdrawal symptoms
* None of participants were receiving any medical treatment

Exclusion Criteria:

* Intracranial hypertension
* Cranial defects
* Tumors
* Serious physical illnesses (e.g., cardiovascular, liver, kidney, gastrointestinal disorders)
* Infectious diseases
* Immune system disorders

Primary outcomes:
measure: The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)
timeFrame: Baseline, week 3, week7
measure: ERP components associated with cognitive function
timeFrame: Baseline, week 3, week7
measure: Condition stop signal task
timeFrame: Baseline, week 3, week7
measure: Neural oscillations associated with cognitive function
timeFrame: Baseline, week 3, week7
measure: Functional connection of brain region associated with cognitive function
timeFrame: Baseline, week 3, week7
measure: Microstate associated with cognitive function
timeFrame: Baseline, week 3, week7
measure: The effect of oxidative stress system on cognitive function
timeFrame: Baseline, week 3, week7
measure: The effect of immune system on cognitive function
timeFrame: Baseline, week 3, week7
measure: The effect of brain derived neurotrophic factor(BDNF) on cognitive function
timeFrame: Baseline, week 3, week7
measure: Genetic mechanism of cognitive function
timeFrame: Baseline, week 3, week7
Secondary outcomes:
measure: Reverse learning task
timeFrame: Baseline, week 3, week7
measure: Beck Depression Scale
timeFrame: Baseline, week 3, week7
measure: Barrett impulse Scale
timeFrame: Baseline, week 3, week7
measure: Degree of insomnia
timeFrame: Baseline, week 3, week7
measure: The Sensitivity to Punishment and Reward Questionnaire
timeFrame: Baseline, week 3, week7
measure: Visual analog scale
timeFrame: Baseline, week 3, week7
measure: The Desires for Drug Questionnaire
timeFrame: Baseline, week 3, week7
measure: Obsessive compulsive drug use scale
timeFrame: Baseline, week 3, week7
measure: Obsessive-compulsive inventory
timeFrame: Baseline, week 3, week7
measure: Thought Control Ability Questionnaire
timeFrame: Baseline, week 3, week7
measure: Thought Suppression Questionnaire
timeFrame: Baseline, week 3, week7
measure: Rumination Questionnaire
timeFrame: Baseline, week 3, week7
measure: Anger Rumination Questionnaire
timeFrame: Baseline, week 3, week7
measure: Beck Anxiety Scale
timeFrame: Baseline, week 3, week7
measure: Emotional Regulation Difficulty Scale
timeFrame: Baseline, week 3, week7
measure: Aggressive questionnair
timeFrame: Baseline, week 3, week7
Other outcomes:
Locations:
city: Mianyang
country: China
facility: Xin Hua Drug Rehabilitation Center
Study officials:
References: